Tau immunotherapy and imaging

Neurodegenerative Diseases

Volumn 13, Issue 2-3, 2014, Pages 103-106

  Sigurdsson, Einar M ^a  

^a NEW YORK UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

Alzheimer's disease; Immunization; Immunotherapy; Neurofibrillary tangles; Tau; Tauopathies; Vaccine

Indexed keywords

ALPHA SYNUCLEIN; AMYLOID BETA PROTEIN; ANTIBODY; SUPEROXIDE DISMUTASE; TAU PROTEIN; CELL PROTEIN; PROTEIN AGGREGATE; SINGLE CHAIN FRAGMENT VARIABLE ANTIBODY;

ACTIVE IMMUNIZATION; ALZHEIMER DISEASE; ARTICLE; BRAIN SLICE; CLEARANCE; COGNITION; COGNITIVE DEFECT; DIAGNOSTIC PROCEDURE; DRUG EFFICACY; ENDOSOME; HUMAN; HUMAN CELL; IMMUNOTHERAPY; INTERNALIZATION; LYSOSOME; MICROGLIA; MOUSE; NEUROIMAGING; NONHUMAN; PASSIVE IMMUNIZATION; PHAGOCYTOSIS; PRIORITY JOURNAL; PROTEIN AGGREGATION; SENILE PLAQUE; TAUOPATHY; CONFERENCE PAPER; DRUG TARGETING; IMMUNIZATION; NEUROBLASTOMA CELL LINE;

ALZHEIMER DISEASE; ANIMALS; HUMANS; IMMUNIZATION; TAU PROTEINS;

EID: 84896837399     PISSN: 16602854     EISSN: 16602862     Source Type: Journal    
DOI: 10.1159/000354491     Document Type: Article

References (30)

1. Aisen PS, Vellas B: Editorial: passive immunotherapy for Alzheimer's disease: what have we learned, and where are we headed? J Nutr Health Aging 2013; 17: 49-50.
2. Gu J, Sigurdsson EM: Immunotherapy for tauopathies. J Mol Neurosci 2011; 45: 690-695.
3. Asuni AA, Boutajangout A, Quartermain D, Sigurdsson EM: Immunotherapy targeting pathological tau conformers in a tangle mouse model reduces brain pathology with associated functional improvements. J Neurosci 2007; 27: 9115-9129.
4. Boutajangout A, Quartermain D, Sigurdsson EM: Immunotherapy targeting pathological tau prevents cognitive decline in a new tangle mouse model. J Neurosci 2010; 30: 16559-16566.
5. Boutajangout A, Ingadottir J, Davies P, Sigurdsson EM: Passive immunization targeting pathological phospho-tau protein in a mouse model reduces functional decline and clears tau aggregates from the brain. J Neurochem 2011; 118: 658-667.
6. Boutajangout A, Rajamohamed Sait HB, Gonzalez V, Sigurdsson EM: Targeting hyperphosphorylated tau protein with a monoclonal antibody at an advanced stage of tau pathology improves cognition in a mouse model. Alzheimers Dement 2011; 7(suppl 4):S480-S481.
7. Krishnamurthy PK, Deng Y, Sigurdsson EM: Mechanistic studies of antibody-mediated clearance of tau aggregates using an ex vivo brain slice model. Front Psychiatry 2011; 2: 59.
8. Gu J, Sigurdsson EM: Efficacy and mechanisms of antibody-mediated clearance of tau aggregates in brain slice model. Soc Neurosci Meeting Abstract 852.12, New Orleans, 2012.
9. Congdon E, Sait H, Boutajangout A, Sigurdsson EM: Tau antibody uptake into neurons strongly correlates with degree of tau pathology and is primarily receptor-mediated via low affinity Fcgamma receptors. Soc Neurosci Meeting Abstract 852.10, New Orleans, 2012.
10. Clavaguera F, Lavenir I, Falcon B, Frank S, Goedert M, Tolnay M: 'Prion-like' templated misfolding in tauopathies. Brain Pathol 2013; 23: 342-349.
11. Walker LC, Diamond MI, Duff KE, Hyman BT: Mechanisms of protein seeding in neurodegenerative diseases. JAMA Neurol 2013; 70: 304-310.
12. Valera E, Masliah E: Immunotherapy for neurodegenerative diseases: focus on alpha-synucleinopathies. Pharmacol Ther 2013; 138: 311-322.
13. Boimel M, Grigoriadis N, Lourbopoulos A, Haber E, Abramsky O, Rosenmann H: Efficacy and safety of immunization with phosphorylated tau against neurofibrillary tangles in mice. Exp Neurol 2010; 224: 472-485.
14. Chai X, Wu S, Murray TK, Kinley R, Cella CV, Sims H, Buckner N, Hanmer J, Davies P, O'Neill MJ, Hutton ML, Citron M: Passive immunization with anti-Tau antibodies in two transgenic models: reduction of Tau pathology and delay of disease progression. J Biol Chem 2011; 286: 34457-34467.
15. Bi M, Ittner A, Ke YD, Gotz J, Ittner LM: Tautargeted immunization impedes progression of neurofibrillary histopathology in aged P301L tau transgenic mice. PLoS One 2011; 6:e26860.
16. Troquier L, Caillierez M, Burnouf S, Fernandez-Gomez FJ, Grosjean MJ, Zommer N, Sergeant N, Schraen-Maschke S, Blum D, Buee L: Targeting phospho-Ser422 by active tau immunotherapy in the THY-Tau22 mouse model: a suitable therapeutic approach. Curr Alzheimer Res 2012; 9: 397-405.
17. Kfoury N, Holmes BB, Jiang H, Holtzman DM, Diamond MI: Trans-cellular propagation of tau aggregation by fibrillar species. J Biol Chem 2012; 287: 19440-19451.
18. d'Abramo C, Acker CM, Jimenez HT, Davies P: Tau passive immunotherapy in mutant P301L mice: antibody affinity versus specificity. PLoS One 2013; 8:e62402.
19. Rosenmann H, Grigoriadis N, Karussis D, Boimel M, Touloumi O, Ovadia H, Abramsky O: Tauopathy-like abnormalities and neurologic deficits in mice immunized with neuronal tau protein. Arch Neurol 2006; 63: 1459-1467.
20. Shin J, Kepe V, Barrio JR, Small GW: The merits of FDDNP-PET imaging in Alzheimer's disease. J Alzheimers Dis 2011; 26(suppl 3):135-145.
21. Fodero-Tavoletti MT, Okamura N, Furumoto S, Mulligan RS, Connor AR, McLean CA, Cao D, Rigopoulos A, Cartwright GA, O'Keefe G, Gong S, Adlard PA, Barnham KJ, Rowe CC, Masters CL, Kudo Y, Cappai R, Yanai K, Villemagne VL: 18F-THK523: a novel in vivo tau imaging ligand for Alzheimer's disease. Brain 2011; 134: 1089-1100.
22. Zhang W, Arteaga J, Cashion DK, Chen G, Gangadharmath U, Gomez LF, Kasi D, Lam C, Liang Q, Liu C, Mocharla VP, Mu F, Sinha A, Szardenings AK, Wang E, Walsh JC, Xia C, Yu C, Zhao T, Kolb HC: A highly selective and specific PET tracer for imaging of tau pathologies. J Alzheimers Dis 2012; 31: 601-612.
23. Chien DT, Bahri S, Szardenings AK, Walsh JC, Mu F, Su MY, Shankle WR, Elizarov A, Kolb HC: Early clinical PET imaging results with the novel PHF-tau radioligand [F-18]-T807. J Alzheimers Dis 2013; 34: 457-468.
24. Zakaib GD: http://www.alzforum.org/new/detail.asp?id=3386; 2013.
25. Lin YJ, Koretsky AP: Manganese ion enhances T1-weighted MRI during brain activation: an approach to direct imaging of brain function. Magn Reson Med 1997; 38: 378-388.
26. Koretsky AP: Is there a path beyond BOLD? Molecular imaging of brain function. Neuroimage 2012; 62: 1208-1215.
27. 2. Magn Reson Med 2002; 48: 852-859.
28. Wadghiri YZ, Blind JA, Duan XH, Moreno C, Yu X, Joyner AL, Turnbull DH: Manganeseenhanced magnetic resonance imaging (MEMRI) of mouse brain development. NMR Biomed 2004; 17: 613-619.
29. Bertrand A, Khan U, Hoang DM, Novikov DS, Krishnamurthy P, Rajamohamed Sait HB, Little BW, Sigurdsson EM, Wadghiri YZ: Non-invasive, in vivo monitoring of neuronal transport impairment in a mouse model of tauopathy using MEMRI. Neuroimage 2013; 64: 693-702.
30. Little BW, Khan U, Rajamohamed Sait H, Hoang DM, Bertrand A, Wadghiri YZ, Sigurdsson EM: Tau immunotherapy improves axonal transport as detected in vivo by manganese-enhanced magnetic resonance imaging. Alzheimers Dement 2012; 8: 38.